-+ 0.00%
-+ 0.00%
-+ 0.00%
Mediar Therapeutics signs collaboration, option deal with Ono Pharma on fibro-inflammatory disease antibodies
Share
Listen to the news
Mediar Therapeutics signs collaboration, option deal with Ono Pharma on fibro-inflammatory disease antibodies
  • Sofinnova Partners portfolio company Mediar Therapeutics signed a collaboration and option deal with Ono Pharmaceutical on antibody programs for fibro-inflammatory diseases.
  • Ono secured an exclusive option for worldwide rights to develop and commercialize the programs; terms include an upfront payment and R&D funding.
  • Mediar will continue advancing MTX-474 (Phase 2 systemic sclerosis), MTX-463 (Phase 2 idiopathic pulmonary fibrosis; with Eli Lilly), MTX-439 (Phase 1 CKD fibrosis).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending